Revenue Breakdown
Composition ()
No data
Revenue Streams
Grail Inc (GRAL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Screening, accounting for 96.7% of total sales, equivalent to $34.38M. Another important revenue stream is Development Services. Understanding this composition is critical for investors evaluating how GRAL navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Grail Inc maintains a gross margin of -37.94%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -346.17%, while the net margin is -245.83%. These profitability ratios, combined with a Return on Equity (ROE) of -16.83%, provide a clear picture of how effectively GRAL converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, GRAL competes directly with industry leaders such as NVST and ICUI. With a market capitalization of $3.81B, it holds a significant position in the sector. When comparing efficiency, GRAL's gross margin of -37.94% stands against NVST's 55.99% and ICUI's 37.41%. Such benchmarking helps identify whether Grail Inc is trading at a premium or discount relative to its financial performance.
